Osimertinib at Lower Dose Effective in EGFR-Mutant NSCLC With Leptomeningeal Metastases
Myung-Ju Ahn, MD, discusses the results from the AURA LM trial and the next steps that need to be taken in order to confirm the efficacy that was seen with the lower dose of osimertinib in patients with EGFR-mutant non–small cell lung cancer with leptomeningeal metastases.
Source: OncLive